Metastatic Tumor

Oncology
5
Pipeline Programs
2
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
4100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Precision BioSciences
4 programs
4
CD70 CAR-T cellsPhase 1Cell Therapy1 trial
CD70 CAR-T cellsPhase 1Cell Therapy1 trial
CD70 CAR-T cellsPhase 1Cell Therapy1 trial
CD70 CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT05420545Unknown36Est. Dec 2024
NCT05420519Unknown24Est. Dec 2024
NCT05468190Unknown48Est. Jul 2025
+1 more trials
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
Pexa-VecPhase 11 trial
Active Trials
NCT02977156CompletedEst. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Precision BioSciencesCD70 CAR-T cells
Precision BioSciencesCD70 CAR-T cells
Precision BioSciencesCD70 CAR-T cells
Precision BioSciencesCD70 CAR-T cells
TransgenePexa-Vec

Clinical Trials (5)

Total enrollment: 138 patients across 5 trials

NCT05468190Precision BioSciencesCD70 CAR-T cells

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Start: Jul 2022Est. completion: Jul 202548 patients
Phase 1Unknown
NCT05518253Precision BioSciencesCD70 CAR-T cells

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start: May 2022Est. completion: May 202730 patients
Phase 1Recruiting
NCT05420545Precision BioSciencesCD70 CAR-T cells

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start: Dec 2021Est. completion: Dec 202436 patients
Phase 1Unknown
NCT05420519Precision BioSciencesCD70 CAR-T cells

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Start: Dec 2021Est. completion: Dec 202424 patients
Phase 1Unknown
NCT02977156TransgenePexa-Vec

Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.

Start: Jan 2017Est. completion: Jun 2022
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 138 patients
Cell Therapy is the dominant modality (100% of programs)
2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)